NCT06023095View on ClinicalTrials.gov

A Study of LY3502970 in Chinese Participants With Obesity or Are Overweight With Weight-related Comorbidities

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 21, 2023

Primary Completion Date

July 29, 2024

Study Completion Date

July 29, 2024

Conditions

OverweightObesity

Interventions

DRUG

LY3502970

Administered orally.

DRUG

Placebo

Administered orally.

Trial Locations (3)

201620

Shanghai General Hospital, Shanghai

510080

Guangdong Provincial People's Hospital, Guangzhou

610041

West China Hospital Sichuan University, Chengdu

All Listed Sponsors

lead

Eli Lilly and Company

INDUSTRY

NCT06023095 - A Study of LY3502970 in Chinese Participants With Obesity or Are Overweight With Weight-related Comorbidities | Biotech Hunter | Biotech Hunter